Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06910306 · ClinicalTrials.gov registry record · NA
A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma
A NA study of Recurrent Glioblastoma and Recurrent Gliomas, sponsored by Alpha Tau Medical.
- Recruiting
- Registry status
- NA
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06910306: Recruiting NA study of Recurrent Glioblastoma and Recurrent Gliomas, sponsored by Alpha Tau Medical.
NCT06910306 is a NA study of Recurrent Glioblastoma and Recurrent Gliomas that is actively recruiting participants, run by Alpha Tau Medical. The registered enrollment target is 10 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06910306, a NA study of Recurrent Glioblastoma and Recurrent Gliomas, is actively recruiting participants, sponsored by Alpha Tau Medical.
- RECRUITING
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
Primary Outcome
Feasibility will be determined according to the rate of successful placement of Alpha DaRT sources into brain tumors.
Conditions Studied
Interventions
- DEVICE Device :DaRT seeds
Study Locations (1)
Ohio
- Ohio State University Medical Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What NCT06910306 shows while recruiting
NCT06910306 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which Device :DaRT seeds is the first listed.
NCT06910306 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06910306 about?
NCT06910306 is a clinical study titled "A Study to Assess the Feasibility and Safety of Intratumoral Diffusing Alpha Emitters for the Treatment of Recurrent Glioblastoma". A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for the treatment of recurrent Glioblastoma
What is the current status of trial NCT06910306?
This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2025-10-01. Estimated completion is 2026-12-01.
What conditions does trial NCT06910306 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Recurrent Gliomas.
What interventions are being tested in trial NCT06910306?
The interventions under investigation include: Device :DaRT seeds (DEVICE).
Who is sponsoring clinical trial NCT06910306?
This trial is sponsored by Alpha Tau Medical, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06910306 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06910306's enrollment target sits among peer trials
10 59th of 62 higher than 4 of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
RECRUITING · NA
-
Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma
RECRUITING · NA
-
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
ACTIVE NOT RECRUITING · NA
-
Mathematical Model-Adapted Radiation In Glioblastoma
COMPLETED · NA
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI